Pulmonary hypertension trials: Current end points are flawed, but what are the alternatives?

Chest

Volumn 130, Issue 4, 2006, Pages 934-936

  Roberts, Kari ^a,b   Preston, Ioana ^a,b   Hill, Nicholas S ^a,b  

^a Tufts New England Medical Center ^*

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TREATMENT OUTCOME; WALKING;

EID: 33750081737     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.4.934     Document Type: Editorial

References (13)

1. American College of Chest Physicians, ACCP evidence-based guidelines for pulmonary arterial hypertension. Chest 2004; 126:1S-92S
2. Rich S. The current treatment of pulmonary arterial hypertension time to redefine success. Chest 2006; 130:1198-1202
3. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006; 97:123-126
4. Eaton T, Young P, Nicol K, et al. The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients. Chron Respir Dis 2006; 3:3-9
5. McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. Eur J Echocardiogr 2006; Apr 29 [Epub ahead of print]
6. Nikolaou K, Schoenberg SO, Attenberger U, et al. Pulmonary arterial hypertension: diagnosis with fast perfusion MR imaging and high-spatial- resolution MR angiography; preliminary experience. Radiology 2005; 236:694-703
7. Bressollette E, Dupuis J, Bonan R, et al. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest 2001; 120:809-815
8. Ritman EL. Micro-computed tomography of the lungs and pulmonary-vascular system. Proc Am Thorac Soc 2005; 2:477-480
9. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27:589-.595
10. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
11. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788
12. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44-54
13. Ray WA. Observational studies of drugs and mortality. N Engl J Med 2005; 353:2319-2321